This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AVANIR Pharmaceuticals (AVNR)

NASDAQ: Health Care

Company Income Statement
Sep 2014 Sep 2013 Sep 2012 Sep 2011
Sales 115.03M 75.37M 41.28M 10.50M
Cost of Sales 1.72M 2.73M 1.21M 8.14K
Gross Operating Profit 113.31M 72.64M 40.07M 10.49M
Selling, General, and Administrative Expenses 113.85M 93.14M 74.49M 55.43M
Research & Development 44.00M 49.51M 23.07M 15.25M
Operating Income before D & A (EBITDA) -44.54M -70.00M -57.49M -60.19M
Depreciation & Amortization 1.80M 1.42M 913.06K 437.84K
Interest Income 20.00K 51.91K 42.82K 38.78K
Other Income - Net -797.00K -31.00 4.08K -37.73K
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -47.12M -71.37M -58.36M -60.63M
Interest Expense 3.31M 4.10M 1.39M 0.00
Pre-Tax Income -50.43M -75.47M -59.74M -60.63M
Income Taxes 3.00K 3.20K 3.20K 3.20K
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -50.44M -75.48M -59.74M -60.63M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -50.44M -75.48M -59.74M -60.63M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -50.44M -75.48M -59.74M -60.63M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-50.44M -75.48M -59.74M -60.63M
Preferred Dividends
Net Income Available To Common -50.44M -75.48M -59.74M -60.63M
Basic EPS from Continuing Ops. -0.31 -0.53 -0.45 -0.51
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -0.31 -0.53 -0.45 -0.51
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -0.31 -0.53 -0.45 -0.51
Basic Normalized Net Income/Share -0.31 -0.53 -0.45 -0.51
EPS fr Continuing Ops. -0.31 -0.53 -0.45 -0.51
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -0.31 -0.53 -0.45 -0.51
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -0.31 -0.53 -0.45 -0.51
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-0.31 -0.53 -0.45 -0.51
Dividends Paid per Share 0.00 0.00 0.00 0.00
AVNR News

AVNR AVANIR Pharmaceuticals

Analysts Ratings for AVNR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 5 3 3
Moderate Buy 0 0 0 0
Hold 3 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET AVNR ANALYST REPORT

Brokerage Partners

AVNR Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs